Is Sunesis Pharmaceuticals Poised for a Breakout?

The little-known biopharma Sunesis Pharmaceuticals is on the cusp of unblinding late-stage trial data for its flagship oncology drug vosaroxin. Leading into this seminal event, management sounds fairly confident of a positive result, but the market clearly has its doubts. Why?

May 8, 2014 at 6:51AM

So far this year, we've seen a handful of developmental-stage oncology companies report positive late-stage data for their therapeutic candidates, resulting in major rallies in their respective share prices. For example, Endocyte, InterMune, and most recently, Merrimack Pharmaceuticals all shot northwards after reporting strong clinical results this year. Sunesis Pharmaceuticals (NASDAQ:SNSS) is hoping to keep this trend alive with its experimental drug for relapsed and refractory acute myeloid leukemia, or AML, known as vosaroxin (trademark Qinprezo). Per the company's first-quarter earnings release, we should now expect a top-line data readout sometime in either the third or fourth quarter of this year. 

What's interesting is that Sunesis' management sounded particularly confident in its first-quarter call that the late-stage trial dubbed "VALOR" would yield a result worthy of a regulatory filing with both the Food and Drug Administration, as well as its European counterpart. Yet, the company's share price has moved steadily south in recent weeks and failed to react to the sunny outlook promulgated on the conference call. 

SNSS Chart

SNSS data. Source: YCharts.

Signs of confidence within Sunesis
Earlier this year, Sunesis created the new position of chief commercial officer and hired Joseph I. DePinto to fill this role. According to his statements in the latest earnings calls, he will specifically help coordinate a U.S. launch of vosaroxin following the forthcoming data readout. So, the company is already investing resources in the drug's commercial launch, which is definitely noteworthy. Secondly, Sunesis recently secured a trademark for vosaroxin in both the U.S. and the EU, namely Qinprezo. Perhaps these actions are equivalent to putting the proverbial cart before the horse since we haven't even seen the unblinded data yet, but management's tone about Qinprezo is certainly upbeat. 

How is the VALOR trial progressing?
Turning to the actual trial, we learned in the recent call that more than 95% of events, a.k.a. deaths, in the VALOR trial have now occurred. Even so, Sunesis's management wasn't able to give a clear timeline for a data readout because of a marked slowing in mortality as the trial progresses. And while that may seem like a signal that the drug is working, you should bear in mind that the sickest patients who were unable to undergo allogeneic stem cell transplant therapy likely passed away first, leaving the comparatively healthier patients to form the so-called "tail" of the study. Indeed, Sunesis Chief Medical Officer Adam Craig noted on the call that the remaining survivors have likely received transplants, increasing their chances of living longer. That said, you need to understand that one of the primary therapeutic goals of this drug is to allow patients to live long enough to receive a transplant in the first place.  

Sunesis is expanding its clinical activities
One of the biggest problems facing small development biotechs is a dearth of additional clinical candidates, making their long-term success wholly dependent on a single experimental therapy. In January, Sunesis sought to deal with this problem by signing licensing agreements with both Biogen (NASDAQ:BIIB) and Takeda Pharmaceutical (NASDAQOTH:TKPYY) in order to expand their footprint in the oncology space. Although these agreements are for early-stage candidates, it's important to note that management is actively seeking to create deep value for shareholders. Moreover, Sunesis gained access to one of the most closely watched types of new oncology therapies with these agreements, namely kinase inhibitors. So, you should keep a close watch on this aspect of this tiny biotech moving forward.

Foolish wrap-up
Despite these positive statements and actions by management this year, the market is clearly unimpressed. Sunesis shares are now down over 12% in the past year and have fallen over 20% in the past month alone.

So why is the market dismissing Sunesis' chances for clinical and regulatory success with Qinprezo? At the end of the day, the truth is that relapsed or refractory AML is notoriously difficult to treat, with no standard of care existing within the U.S.. My view is that the market firmly believes Qinprezo will ultimately fail in clinical trials due to the difficulty of treating this indication. That said, the utter lack of treatments for relapsed AML may play into Qinprezo's favor. Simply put, we may not need a stunning result to convince regulators that Qinprezo should be approved, i.e., even a marginal clinical benefit could be viewed as a basis for a regulatory approval. And that's why I think Sunesis' management is gaining confidence heading into this top-line data readout, making this biotech one to get on your watchlist.  

Invest in the next wave of health-care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind it is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential and its ability to make life-changing medical solutions never thought possible.  To learn how you can invest in this unbelievable new technology, click here now to see our free report.

George Budwell has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers